Somaform's Interface Line Stays Under Review as Regulators Weigh Conditions

Regulators pressed Somaform Augmetics' newest neural-interface line back into another round of scrutiny this week — and the word that mattered was the qualifier. Unresolved. Deep into a lengthy safety review that shows no sign of closing, the Concordat's augmentation authority signalled that any path to market would carry a regime of staged rollout, mandatory monitoring, and a hard cap on the depth of integration the line may offer — terms the company is contesting with visible reluctance. Somaform founder Julian Morrow, long an advocate for augmentation as a matter of personal liberty, called the mooted conditions "a compromise the technology has outgrown." His critics called them the minimum. Between those poles sits the question the review has reopened and not resolved — the oldest one in the field. How much is too much? A neural interface that reads intention and returns sensation is a medical marvel and a philosophical trapdoor, and the regulators, in effect, have declined to answer, choosing instead to keep watching before they permit. "We are not qualified to say where a person ends and a device begins," one authority member conceded. "We are only qualified to slow down the finding out." The line stays in review, into a debate no ruling can close.